This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneider, P. M. Articles by Siewert, J. R. Search for Related Content PubMed PubMed Citation Articles by Schneider, P. M. Articles by Siewert, J. R.

p53 Mutational Status Improves Estimation of Prognosis in Patients with Curatively Resected Adenocarcinoma in Barrett’s Esophagus¹

Departments of Surgery [P. M. S., O. S., A. H. H., S. W., S. M., H-J. D., U. F., J. R. S.] and Pathology [K. B.], Technische Universitaet Muenchen, Munich, Germany, and Department of Thoracic and Cardiovascular Surgery, M. D. Anderson Cancer Center, Houston, Texas 77030 [J. A. R.]

The incidence of adenocarcinomas in Barrett’s esophagus has been rising in the last two decades in the United States and Western Europe for yet unknown reasons. We reported previously a large multi-institutional trial implicating p53 mutations as being involved in the pathogenesis of Barrett’s cancer and representing an early marker for the malignant potential of Barrett’s epithelium. A prospective study was performed to evaluate the prognostic impact of p53 mutations on survival in 59 patients with Barrett’s cancer. Tissue for DNA analysis was obtained by endoscopic biopsy or immediately after surgical resections from the tumor, Barrett’s epithelium, and normal stomach and esophagus. p53 mutation analysis was performed by PCR-single strand conformational polymorphism screening of exons 5–9 and DNA sequencing to unequivocally prove the presence of a mutation. p53 mutations were identified in 30 of 59 (50.8%) patients. The presence of a p53 mutation in the tumor had a significant impact on survival after curative resections (RO-resections) with cumulative 5-year survival probabilities of 68.8 ± 9.7% for mutation-negative tumors and 24.3 ± 9.9% for mutation-positive tumors (log rank: P < 0.001). By Cox proportional hazard analysis, including the parameters of gender, age, Union International Contre Cancer tumor stage, grading, and p53 mutation status, only Union International Contre Cancer tumor stage (P < 0.0001) and p53 mutation status (P < 0.02) were of significant independent prognostic importance. p53 mutation analysis by DNA sequencing is of significant independent prognostic importance next to histopathological tumor stage in patients with curatively resected (RO-resection) Barrett’s cancer. It appears that p53 mutational status is a valuable parameter to define low-risk (p53 mutation-negative) and high-risk (p53 mutationpositive) groups for treatment failure after curative resections.

This article has been cited by other articles:

				S. M. Lagarde, F. J. W. ten Kate, D. J. Richel, G. J. A. Offerhaus, and J. J. B. van Lanschot Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction Ann. Surg. Oncol., February 1, 2007; 14(2): 977 - 991. [Abstract] [Full Text] [PDF]

				R Langer, B H A Von Rahden, J Nahrig, C Von Weyhern, R Reiter, M Feith, H J Stein, J R Siewert, H Hofler, and M Sarbia Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J. Clin. Pathol., June 1, 2006; 59(6): 631 - 634. [Abstract] [Full Text] [PDF]

				S. R. DeMeester Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment Ann. Surg. Oncol., January 1, 2006; 13(1): 12 - 30. [Abstract] [Full Text] [PDF]

				F. Le Calvez, A. Ahman, N. Tonisson, J. Lambert, S. Temam, P. Brennan, D. G. Zaridze, A. Metspalu, and P. Hainaut Arrayed Primer Extension Resequencing of Mutations in the TP53 Tumor Suppressor Gene: Comparison with Denaturing HPLC and Direct Sequencing Clin. Chem., July 1, 2005; 51(7): 1284 - 1287. [Full Text] [PDF]

				G.J.S. Jenkins REVIEW The restriction site mutation (RSM) method: clinical applications Mutagenesis, January 1, 2004; 19(1): 3 - 11. [Abstract] [Full Text] [PDF]

				A. G. Casson, S. C. Evans, A. Gillis, G. A. Porter, P. Veugelers, S. J. Darnton, D. L. Guernsey, and P. Hainaut Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1121 - 1131. [Abstract] [Full Text] [PDF]

				J. Breton, F. Sichel, A. Abbas, J. Marnay, D. Arsene, and M. Lechevrel Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France) Mutagenesis, May 1, 2003; 18(3): 299 - 306. [Abstract] [Full Text] [PDF]

				X. Chen and C. S. Yang Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention Carcinogenesis, August 1, 2001; 22(8): 1119 - 1129. [Abstract] [Full Text] [PDF]